Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America
Objectives. To map the timing and nature of regulatory reliance pathways used to authorize COVID-19 vaccines in Latin America. Methods. An observational study was conducted assessing the characteristics of all COVID-19 vaccine authorizations in Latin America. For every authorization it was determined whether reliance was used in the authorization process. Subgroups of reference national regulatory authorities (NRAs) and non-reference NRAs were compared. Results. 56 authorizations of 10 different COVID-19 vaccines were identified in 18 countries, of which 25 (44.6%) used reliance and 12 (21.4%) did not. For the remaining 19 (33.0%) it was not possible to determine whether reliance was used. Reference agencies used reliance less often (40% of authorizations with a known pathway) compared to non-reference agencies (100%). The median review time was just 15 days and does not meaningfully differ between reliance and non-reliance authorizations. Conclusions. This study demonstrated that for these vaccines, despite reliance pathways being associated with numerous rapid authorizations, independent authorization review times were not considerably longer than reliance reviews; reliance pathways were not a prerequisite for rapid authorization. Nevertheless, reliance pathways provided rapid authorizations in response to the COVID-19 emergency..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Revista Panamericana de Salud Pública - 46(2022), 115, Seite 7 |
| Sprache: |
Englisch ; Spanisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Ivar T. van der Zee [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.26633/RPSP.2022.115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ024110310 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ024110310 | ||
| 003 | DE-627 | ||
| 005 | 20230526113031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26633/RPSP.2022.115 |2 doi | |
| 035 | |a (DE-627)DOAJ024110310 | ||
| 035 | |a (DE-599)DOAJ1da238bafa3f4166b3fe1a754b4fa907 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa |a por | ||
| 050 | 0 | |a RC955-962 | |
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Ivar T. van der Zee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives. To map the timing and nature of regulatory reliance pathways used to authorize COVID-19 vaccines in Latin America. Methods. An observational study was conducted assessing the characteristics of all COVID-19 vaccine authorizations in Latin America. For every authorization it was determined whether reliance was used in the authorization process. Subgroups of reference national regulatory authorities (NRAs) and non-reference NRAs were compared. Results. 56 authorizations of 10 different COVID-19 vaccines were identified in 18 countries, of which 25 (44.6%) used reliance and 12 (21.4%) did not. For the remaining 19 (33.0%) it was not possible to determine whether reliance was used. Reference agencies used reliance less often (40% of authorizations with a known pathway) compared to non-reference agencies (100%). The median review time was just 15 days and does not meaningfully differ between reliance and non-reliance authorizations. Conclusions. This study demonstrated that for these vaccines, despite reliance pathways being associated with numerous rapid authorizations, independent authorization review times were not considerably longer than reliance reviews; reliance pathways were not a prerequisite for rapid authorization. Nevertheless, reliance pathways provided rapid authorizations in response to the COVID-19 emergency. | ||
| 650 | 4 | |a regulatory frameworks | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a health priorities | |
| 650 | 4 | |a latin america | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a drug approval | |
| 650 | 4 | |a covid-19 vaccines | |
| 650 | 4 | |a drug utilization review | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Arctic medicine. Tropical medicine | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Rick A. Vreman |e verfasserin |4 aut | |
| 700 | 0 | |a Lawrence Liberti |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Alanis Garza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista Panamericana de Salud Pública |d Pan American Health Organization, 2018 |g 46(2022), 115, Seite 7 |w (DE-627)DOAJ000129496 |x 16805348 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g number:115 |g pages:7 |
| 856 | 4 | 0 | |u https://doi.org/10.26633/RPSP.2022.115 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/1da238bafa3f4166b3fe1a754b4fa907 |z kostenfrei |
| 856 | 4 | 0 | |u https://iris.paho.org/handle/10665.2/56287 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1020-4989 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1680-5348 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |e 115 |h 7 | ||